Search clinical trials for: TAK-063 Placebo

Total 58468 results

Takeda

Completed

Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants

Schizophrenia

United States
Takeda

Completed

A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia

Schizophrenia

United States
Takeda

Recruiting

A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India

Healthy Volunteers

India
Takeda

Completed

Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue

Dengue Fever

United States
Takeda

Active, not recruiting

A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

Celiac Disease

United States, Belgium, Poland, Italy, Canada, United Kingdom, France, Spain
Takeda

Completed

An [^11C]T-773 Positron Emission Tomography (PET) Study to Determine Phosphodiesterase10A Occupancy by TAK-063

Healthy Volunteers
Takeda

Completed

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults

Dengue

United States
Takeda

Available

Expanded Access to TAK-113 for Adults With Metastatic Colorectal Cancer (mCRC)

Colorectal Cancer
Takeda

Completed

Single-Dose Phase 1 Study of TAK-792

Healthy Male Adults Participants

Japan
Takeda

Completed

Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults

Ketamine-Induced Brain Activity Changes | Psychotic-like Symptoms

United States
Athos Therapeutics Inc
Syneos Health; Athos Therapeutics Australia Pty Ltd

Completed

Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATH-063 in Healthy Subjects

Autoimmune Diseases | Inflammatory Bowel Diseases | Crohn Disease | Ulcerative Colitis

Australia
Takeda

Withdrawn

A Phase 1, Single and Multiple Dose Study of TAK-137

Healthy Japanese Adult Male

Japan
Takeda

Withdrawn

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in Adults

Coronavirus Disease
Takeda

Completed

A Study of TAK-951 in Healthy Adults

Healthy Volunteers

United States
Takeda

Completed

A Study of TAK-951 in Healthy Adults

Healthy Volunteer

United States
Takeda

Terminated

Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.

Attention-Deficit/Hyperactivity Disorder

United States
Takeda

Terminated

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Cardiovascular Disease | Type 2 Diabetes

United States, France, Poland, Ukraine, Germany, Hong Kong, Taiwan, Argentina, Israel, Mexico, Bulgaria, Malaysia, Romania, Canada, Korea, Republic of, New Zealand, Peru, Estonia, Philippines, Russian Federation, Czech Republic, H... and more
Millennium Pharmaceuticals, Inc.

Completed

A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia

Idiopathic Hypersomnia

United States, Japan
Takeda

Withdrawn

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-988 in Healthy Participants

Healthy Volunteers

United States
Neurocrine Biosciences
Takeda

Completed

Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia

Friedreich Ataxia

United States
Takeda

Completed

Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Male Participants

Japanese Healthy Adult Male Participants

Japan
Takeda

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Participants

Healthy Participants

United States
Takeda

Completed

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Oral Single Dose of TAK-418 in Healthy Participants

Healthy Participants

United States
Takeda

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-438 in Healthy Male Participants

Dose Finding Study
Pfizer

Terminated

A Study In Healthy Subjects Of Single Doses of PF-05230901 Injected Under The Skin

Cachexia

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus | Lupus Erythematosus, Systemic

United States
Takeda
Takeda Development Center Americas, Inc.

Completed

A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery

Postoperative Gastrointestinal Dysfunction

United States, Germany
Neurocrine Biosciences
Takeda

Completed

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

Schizophrenia | Healthy Volunteers

United States
Neurocrine Biosciences
Takeda

Completed

TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants

Depressive Disorder

United Kingdom
Millennium Pharmaceuticals, Inc.

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-954 in Healthy Adult Participants

Healthy Volunteers

United States
Takeda

Terminated

Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes (GRAND-307)

Type 2 Diabetes Mellitus

Taiwan, China, Korea, Republic of, New Zealand, Australia
Takeda

Completed

TAK-438 - Safety, Blood Levels & Effects of Repeated Doses (TAK-438_107)

Gastroesophageal Reflux Disease (GERD) | Erosive Esophagitis(EE)

United Kingdom
Takeda
Takeda Development Center Americas, Inc.

Terminated

A Study of TAK-018 in Preventing the Recurrence of Crohn's Disease After Surgery

Crohn Disease

United States, Germany, Austria, France, United Kingdom
Millennium Pharmaceuticals, Inc.

Terminated

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Oral Dose of TAK-418 in Healthy Female Participants

Healthy Volunteers

United States
Takeda

Completed

A Study of TAK-079 in People With Generalized Myasthenia Gravis

Myasthenia Gravis

United States, Spain, Canada, Serbia, Italy, Poland
Neurocrine Biosciences
Takeda

Terminated

A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants

Schizophrenia, Cerebellar Ataxia

United Kingdom
Rhodes Pharmaceuticals, L.P.
Purdue Pharma LP

Completed

PRC-063 in Adolescent ADHD

ADHD

United States, Canada
Rhodes Pharmaceuticals, L.P.
Purdue Pharma, Canada

Completed

The Efficacy and Safety of PRC-063 in Adult ADHD Patients

ADHD

United States, Canada
Samsung Bioepis Co., Ltd.

Completed

A Phase I Study of SB26 in Healthy Volunteers

Healthy Volunteers

United States
Takeda

Completed

A Study of TAK-105 in Healthy Adults

Healthy Volunteers

United States
Rhodes Pharmaceuticals, L.P.
Purdue Pharma LP

Completed

PRC-063 in an ADULT Workplace Environment

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Henan Cancer Hospital

Not yet recruiting

Application of Douyin in Perioperative Period of Malignant Tumor Patients

Perioperative Period | Malignant Tumor of Bone
Huahui Health

Recruiting

A Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus Infection

Chronic Hepatitis Delta Virus Infection

China
Henan Cancer Hospital

Not yet recruiting

Application of Douyin in Patients With Bone and Soft Tissue Malignant Tumors During Perichemotherapy

Chemotherapy | Malignant Tumor
Neurocrine Biosciences
Takeda

Completed

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants

Healthy

United States
Kaohsiung Medical University Chung-Ho Memorial...

Completed

Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRI

Colorectal Cancer

Taiwan
Takeda

Completed

TAK-114 Single- and Multiple-Dose Phase 1 Study

Clinical Pharmacology

Japan
Takeda

Completed

A Study of TAK-861 in Participants With Narcolepsy Type 2

Narcolepsy Type 2

Spain, United States, Japan, Italy, France, Germany, Australia, Netherlands, Finland, Norway, Sweden, Switzerland
Takeda

Completed

Phase 1 TAK-925 Study in Healthy Adult and Elderly Volunteers and Participants With Narcolepsy

Healthy Participants and Patients With Narcolepsy

Japan
Takeda

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics (PK) of Oral TAK-994 in an Acute Sleep Phase Delay Paradigm in Healthy Male Participants

Healthy Volunteers

United States

3

Subscribe